Auxilium's (AUXL) Testosterone Gel Growth Encouraging, Say Analysts
- Wall St set to open flat ahead of Easter break, eyes sharp Q1 gains
- Home Depot agrees to buy SRS Distribution, sees TAM expanding to $1 trillion
- Yen on intervention watch; Asia shares creep higher
- Dollar gains as inflation data looms; yen on intervention watch
- Piper Sandler: Stock rally likely to continue on rising recession risks
- Discover Financial Services (DFS) Announces CEO Resignation
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Timken (TKR) Appoints Tarak Mehta as New CEO
- Crude Inventory Increases 3.2 Million Barrels
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
Auxilium Pharmaceuticals (AUXL) Posts Q3 Loss of 21c/Share; Boosts FY12 Outlook
November 7, 2012 7:30 AM ESTAuxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) reported Q3 EPS of ($0.21), $0.17 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $71 million versus the consensus estimate of $79.35 million.
Sees FY2012 revenue of $388-408 million, versus prior guidance of $310-331 million and the... More